Porton Biopharma
Porton Biopharma signs potential $24m deal to push its intranasal anthrax vaccine into Phase 1 trials
October 22, 2019Manufacturing and Production, Research and Development FDA, Porton Biopharma, anthrax, pharma
Porton Biopharma has signed a modification to its existing agreement with the US National Institute of Health’s National Institute of …
Top Ten most popular articles on Pharmafile.com this week
May 4, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing BMS, EMA, Kymriah, Novartis, Porton Biopharma, Regeneron, Roche, Sandoz, Sanofi, Shire, Takeda, biosimilars, dementia
It’s Friday again and it’s been a week busy with companies’ financials. One company’s in particular were of note due …
Porton Biopharma opens new leukaemia drug production facility
May 1, 2018Manufacturing and Production Porton Biopharma, leukaemia, pharma
Porton Biopharma Limited (PBL) has officially opened the doors of its new fermentation facility. John Glen, MP for Salisbury and …
Jazz Pharmaceuticals UK supplier hit with FDA warning
January 26, 2017Manufacturing and Production Erwinaze, Porton Biopharma, jazz pharmaceuticals
UK-based Porton Biopharma, supplier of Irish company Jazz Pharmaceuticals’ leukaemia treatment Erwinaze, has been slapped with an FDA warning letter …
Latest content
Jager-van Dijk is new Arletta Pharma Solutions CEOÂ
Tridem begins phase Ib trial of Parkinson’s disease vaccine
Trio become latest Symbiosis commercial additions
UK immunoglobulin supply faces growing pressure, report warns
